About this trial
Synopsis Title of Study A prospective, randomized, single blind multicentre phase III study on organ preservation with Custodiol-N compared with Custodiol solution in organ transplantation (kidney, liver and pancreas)
Protocol number: CL-N-KLP-TX-III/07-AT/17
Trial design The study design is a prospective, randomized, single blind, multicentre, phase III comparison study of organ perfusion intended to demonstrate non-inferiority of Custodiol-N against Custodiol in organ transplantation of kidney, combined kidney-pancreas and liver.
Intended duration of study The overall duration for the trial is expected to be approximately 30 months. The du-ration of the trial for each subject is expected to be 3 months (transplantation and a follow-up period of 90 days).
Purpose of the study
The objective of this investigation is to demonstrate non-inferiority of graft preservation with Custodiol-N compared to Custodiol with respect to both graft function and injury after transplantation of kidney, liver or combined kidney-pancreas.
Patient selection The study population will be selected from patients who will undergo kidney, liver or combined kidney-pancreas transplantation. Patients of each gender will be included in the study.
Planned number of patients (recipients)
In total N=362 including:
Kidney 242 (including approx. 30 combined kidney-pancreas)
Liver 120
Eligibility criteria
Qualifiers
All organs (kidney, combined kidney - pancreas and liver) Donor criteria
recipients awaiting their transplant
recipients ≥18 years
recipients' signed informed consent before the transplantation Kidney / combined kidney - pancreas recipients
Disqualifiers
All organs (kidney, combined kidney - pancreas and liver) Donor criteria (not applicable for living kidney donors)
- donors whose organs are all allocated out of retrieving study center
general refusal of organ donation
donation after cardiac death (DCD) Patient (recipient) criteria
Trial design
Treatments tested in this trial
- Custodiol-N Solution
- Custodiol HTK Solution
Treatment groups
6
Treatment groupsSee each treatment group below.